ArticleBMC cancer2026
Quality of life in breast cancer survivors: insights from a university hospital in Sri Lanka.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the leading cancer among females in Sri Lanka. Understanding quality of life (QoL) among survivors is essential for comprehensive cancer care. This study aimed to assess QoL and identify associated factors among breast cancer survivors treated at a university hospital in Sri Lanka.
methodsThis cross-sectional study included 112 breast cancer survivors treated between May 2019 and May 2022. QoL was assessed using validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ-C30 and QLQ-BR23). Descriptive statistics, correlation analyses, and linear regression models were used to identify factors associated with QoL domains.
resultsThe mean age of survivors was 61.15 (± 13.42) years. The mean Quality of Life (QoL) domain score of the EORTC QLQ-C30 was 68.2 (SD 17.5), indicating generally good QoL among participants. Age was significantly negatively correlated with overall QoL (r = -0.31, p = 0.001) and physical functioning (r = -0.29, p = 0.002), and positively correlated with systemic therapy side effects (r = 0.24, p = 0.011) and sexual functioning (r = 0.22, p = 0.020). Larger tumor size was associated with lower physical functioning (r = -0.23, p = 0.015) and poorer body image (p = 0.018). A higher number of radiotherapy fractions was associated with lower sexual functioning (r = -0.26, p = 0.006).
conclusionsBreast cancer survivors demonstrated generally good QoL, with age emerging as a significant determinant. These findings highlight the importance of age-appropriate supportive interventions and integrating QoL assessment into routine survivorship care in Sri Lanka. Clinicians should focus on addressing physical functioning in older survivors and managing treatment side effects to optimize QoL across all age groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.